AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

2021/05/26 by Siddharth Singh, Deborah Proctor, Deborah D. Proctor +4 · 27 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Microscopic Colitis #Autoimmune and Inflammatory Disorders

paper · doi:10.1053/j.gastro.2021.04.023

Citations

• Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
• The Natural History of Adult Crohn's Disease in Population-Based Cohorts
• Quantifying Publication Bias in Meta-Analysis
• Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Cited by

• AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis
• AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. [europepmc]
• Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. [europepmc]
• No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. [europepmc]
• Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases. [europepmc]
• How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease. [europepmc]
• Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. [europepmc]
• Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. [europepmc]
• Biologics: how far can they go in Crohn's disease? [europepmc]
• Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. [europepmc]
• Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn's disease. [europepmc]
• Development and validation of multiparametric models based on computed tomography enterography to determine endoscopic activity and surgical risk in patients with Crohn's disease: A multi-center study. [europepmc]
• Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study. [europepmc]
• Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. [europepmc]
• Perianal Fistula; from Etiology to Treatment - A Review. [europepmc]
• Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease. [europepmc]
• Common Mistakes in Managing Patients with Inflammatory Bowel Disease. [europepmc]
• Extracellular Vesicles Delivered by a Nanofiber-Hydrogel Composite Enhance Healing In Vivo in a Model of Crohn's Disease Perianal Fistula. [europepmc]
• Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. [europepmc]
• Total fistula volume predicts surgical outcomes in complex perianal fistulizing Crohn's disease following fistula-tract laser closure: a single-center retrospective study. [europepmc]
• Characteristics and long-term outcomes of children with perianal Crohn's disease. [europepmc]
• Gender Differences in Coping Strategies and Life Satisfaction Following Cognitive-Behavioral and Mindfulness-Based Intervention for Crohn's Disease: A Randomized Controlled Trial. [europepmc]
• British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. [europepmc]
• Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China. [europepmc]
• Exosomal miR-93-3p targets EIF4EBP1 to regulate macrophage polarization and accelerate wound healing post-anal fistula surgery. [europepmc]
• AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. [europepmc]